PMID- 22129888
OWN - NLM
STAT- MEDLINE
DCOM- 20121008
LR  - 20181201
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 48
IP  - 12
DP  - 2012 Aug
TI  - The characteristics and immunoregulatory functions of regulatory dendritic cells 
      induced by mesenchymal stem cells derived from bone marrow of patient with 
      chronic myeloid leukaemia.
PG  - 1884-95
LID - 10.1016/j.ejca.2011.11.003 [doi]
AB  - Dendritic cells (DCs) are specialised antigen-presenting cells that play crucial 
      roles in the initiation and regulation of immune responses. Recently, mesenchymal 
      stem cells (MSCs) have gained further interest after demonstration of 
      immunomodulatory effects on complicated interactions between T cells and even 
      DCs. However, the mechanisms underlying these immunoregulatory effects of MSCs 
      induced DCs are poorly understood. In addition, it is unclear whether the 
      immunoregulatory functions of MSCs are altered in disease states. In this study, 
      we showed that chronic myeloid leukaemia (CML) patients bone marrow derived MSCs 
      (CML-MSC) could differentiate mature DCs (mDCs) into a distinct regulatory DC 
      population, they had lower expression of CD40, CD80, CD83 and CD86. Similar to 
      immature DCs (imDCs), CML-MSC induced DCs (CML-MSC-DCs) displayed powerful 
      phagocytic capacity. Moreover, CML-MSC-DCs had the capacity to induce T cell 
      anergy, another capacity of regulatory DCs. CML-MSC-DCs could inhibit the 
      proliferation of T cells not only through TGF-beta1, but also by inducing the 
      production of Treg cells or T-cell anergy. At last, CML-MSC-DCs could efficiently 
      induce more CD4+CD25+Foxp3+Tregs from naive CD4+CD25-Foxp3-T cells than that of 
      normal-MSC-DCs in vitro. CML-MSC-DCs derived TGF-beta1 was largely responsible for 
      the increase in CD4+CD25+Foxp3+Tregs based on knockdown studies. The 
      immunoregulatory effects of DCs induced by CML-MSCs enhance the potential use of 
      autologous MSCs in cell therapy.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Zhao, Zhi-Gang
AU  - Zhao ZG
AD  - Department of Haematology and Oncology, The Oncology Hospital of Tianjin Medical 
      University, Tianjin, PR China. zhaodor001@gmail.com
FAU - Xu, Wen
AU  - Xu W
FAU - Sun, Li
AU  - Sun L
FAU - Li, Wei-Ming
AU  - Li WM
FAU - Li, Qiu-Bai
AU  - Li QB
FAU - Zou, Ping
AU  - Zou P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111128
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
SB  - IM
MH  - Adult
MH  - Bone Marrow/*immunology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Humans
MH  - *Immunomodulation
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*immunology
MH  - Male
MH  - Mesenchymal Stem Cells/*immunology
MH  - Middle Aged
MH  - T-Lymphocytes/immunology
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Young Adult
EDAT- 2011/12/02 06:00
MHDA- 2012/10/09 06:00
CRDT- 2011/12/02 06:00
PHST- 2011/05/10 00:00 [received]
PHST- 2011/11/01 00:00 [revised]
PHST- 2011/11/02 00:00 [accepted]
PHST- 2011/12/02 06:00 [entrez]
PHST- 2011/12/02 06:00 [pubmed]
PHST- 2012/10/09 06:00 [medline]
AID - S0959-8049(11)00876-8 [pii]
AID - 10.1016/j.ejca.2011.11.003 [doi]
PST - ppublish
SO  - Eur J Cancer. 2012 Aug;48(12):1884-95. doi: 10.1016/j.ejca.2011.11.003. Epub 2011 
      Nov 28.